Shane Romanchick is a TV and Movie News author for Collider. He also runs his own blog Entershanement Reviews where he writes about and reviews the latest movies. He graduated from Regis College in ...
Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...
Hosted on MSN
Werewolf Therapeutics (HOWL) eyes 2026 catalysts following FDA guidance and encouraging INDUKINE results
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is included on our list of stocks under $1 that will explode. Copyright: epstock / 123RF Stock Photo On December 18, 2025 ...
Jefferies issued a Buy rating on Werewolf Therapeutics (NASDAQ:HOWL) on Tuesday, citing an attractive valuation in the cancer-focused biotech ahead of a data readout scheduled in Q4 2023 for WTX-124, ...
On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline update in which it highlighted clinical progress and 2026 priorities for its INDUKINE programs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results